glp-1 gip therapy weight management benefits The GLP-1/GIP dual-receptor agonist tirzepatide led to at least 15% loss of total body fat in premenopausal, perimenopausal, and postmenopausal women, but postmenopausal women taking menopausal hormone had the greatest The expanding benefits of GLP-1

Recalls & Warnings September 15, 2025 Lead Found in Organic Ground Cinnamon On September 12, 2025, the FDA warned consumers not to buy or use Jiva Organics Organic Cinnamon Powder because it contains elevated levels of lead

Interactions CYP: In vivo, one study reported increased or decreased expression of different isoforms (Olsozowy 2006)

Key metabolic markers: HbA1c is the more reliable indicator

These achieve substantially greater LDL reductions than the modest 17% decreases observed with GLP-1 receptor agonists

The oral route tablets or capsules is genuinely effective for gastrointestinal applications specifically

In patients with obesity (mean age 51.3 years, 65.6% women), semaglutide compared with non-GLP-1RA anti-obesity medications was associated with lower risk for incident CUD in patients with no prior history CUD (HR: 0.56, 95% CI: 0.420.75), and recurrent CUD diagnosis in patients with a prior history CUD (HR: 0.62, 95% CI: 0.460.84)